Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Redmond, founder and CEO of Dr. Stephanie’s Supplements, showcased her products, which she described as the latest innovations in supplement options for hormone and metabolic health, including a ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...